BioCentury
ARTICLE | Clinical News

Fovista: Phase IIa started

August 18, 2014 7:00 AM UTC

Ophthotech began an open-label, U.S. Phase IIa trial to evaluate Fovista in combination with anti-VEGF therapy in about 100 patients with wet AMD. Fovista is in Phase III testing to treat wet AMD, with top-line data expected in 2016. ...